Evidence map›Paper›PMID 36189795›Full record

ArticleThe Journal of clinical investigation2022

Increased core body temperature exacerbates defective protein prenylation in mouse models of mevalonate kinase deficiency.

Marcia A Munoz, Oliver P Skinner, Etienne Masle-Farquhar, Julie Jurczyluk, Ya Xiao, Emma K Fletcher, Esther Kristianto, Mark P Hodson, Seán I O'Donoghue, Sandeep Kaur and 10 more

Open access · goldAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Case Report: Clinical application of anFrontiers in pediatrics · 2025
    Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Marcia A MunozGarvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Oliver P SkinnerGarvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Etienne Masle-FarquharGarvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Julie JurczylukGarvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Ya XiaoGarvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Emma K FletcherGarvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Esther KristiantoVictor Chang Cardiac Innovation Centre, Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia.
Mark P HodsonSchool of Pharmacy, University of Queensland, Woolloongabba, Queensland, Australia.
Seán I O'DonoghueGarvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Sandeep KaurGarvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Robert BrinkGarvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
David G ZahraGarvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Elissa K DeenickGarvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Kristen A PerryGarvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Avril Ab RobertsonSchool of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Queensland, Australia.
Sam MehrRoyal Children's Hospital, Melbourne, Victoria, Australia.
Pravin HissariaRoyal Adelaide Hospital, SA Pathology and University of Adelaide, Adelaide, South Australia, Australia.
Catharina M Mulders-MandersDepartment of Internal Medicine, Radboudumc Expertise Centre for Immunodeficiency and Autoinflammation, Radboud University Medical Centre, Nijmegen, Netherlands.
Anna SimonDepartment of Internal Medicine, Radboudumc Expertise Centre for Immunodeficiency and Autoinflammation, Radboud University Medical Centre, Nijmegen, Netherlands.
Michael J RogersGarvan Institute of Medical Research and School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Garvan Institute of Medical Research · AURadboud University Nijmegen · NLThe University of Queensland · AURoyal Adelaide Hospital · AURoyal Children's Hospital · AUVictor Chang Cardiac Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mevalonate kinase deficiency (MKD) is characterized by recurrent fevers and flares of systemic inflammation, caused by biallelic loss-of-function mutations in MVK. The underlying disease mechanisms and triggers of inflammatory flares are poorly understood because of the lack of in vivo models. We describe genetically modified mice bearing the hypomorphic mutation p.Val377Ile (the commonest variant in patients with MKD) and amorphic, frameshift mutations in Mvk. Compound heterozygous mice recapitulated the characteristic biochemical phenotype of MKD, with increased plasma mevalonic acid and clear buildup of unprenylated GTPases in PBMCs, splenocytes, and bone marrow. The inflammatory response to LPS was enhanced in compound heterozygous mice and treatment with the NLRP3 inflammasome inhibitor MCC950 prevented the elevation of circulating IL-1β, thus identifying a potential inflammasome target for future therapeutic approaches. Furthermore, lines of mice with a range of deficiencies in mevalonate kinase and abnormal prenylation mirrored the genotype-phenotype relationship in human MKD. Importantly, these mice allowed the determination of a threshold level of residual enzyme activity, below which protein prenylation is impaired. Elevated temperature dramatically but reversibly exacerbated the deficit in the mevalonate pathway and the defective prenylation in vitro and in vivo, highlighting increased body temperature as a likely trigger of inflammatory flares.

Indexed as

Mevalonate Kinase DeficiencyAnimalsBody TemperatureFeverGTP PhosphohydrolasesHumansInflammasomesLipopolysaccharidesMevalonic AcidMiceNLR Family, Pyrin Domain-Containing 3 ProteinPhosphotransferases (Alcohol Group Acceptor)Protein PrenylationGTP PhosphohydrolasesInflammasomesLipopolysaccharidesMevalonic AcidNLR Family, Pyrin Domain-Containing 3 ProteinPhosphotransferases (Alcohol Group Acceptor)Autoimmune diseasesInflammationMacrophagesMetabolismMonogenic diseases

Identifiers

PMID36189795
PMCPMC9525117
OpenAlexW4300003375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.